“Efficacy and safety of eltrombopag as thromboyetic agent in the treatment of immune thrombocytopenic purpura in patients that started treatment at Complejo Asistencial Universitario de León during the period 2012-2015
Abstract Immune thrombocytopenic purpura (ITP) is an autoinmune chronic disease that can lead to platelet count under 100.000/?L. Patients may develop purpuric lesions with possible hemorrhagic events. The diagnosis is made by exclusion and the treatment target is to obtain a platelet count superior to 100.000/?L. Eltrombopag is an oral thrombopoietin receptor agonist, indicated for the second-line pharmacological treatment in splenectomized patients with chronic ITP and refractoriness to other treatments. The objetive of this study is to determine the efficacy and safety of the treatment. For this purpose, the dispensation registry and clinical histories of the treated patients during the period of 2012-2015 from Complejo Asistencial Universitario de León were revised. Once the data was compiled and meticulously analysed, it can be concluded that: Most of the studied patients were able to reach the therapeutic target even though the platelet evolution didn't follow a linear progression, and the principal cause of suspension of the treatment was due to weak side effects
- Referencias
- Cómo citar
- Del mismo autor
- Métricas
“Efficacy and safety of eltrombopag as thromboyetic agent in the treatment of immune thrombocytopenic purpura in patients that started treatment at Complejo Asistencial Universitario de León during the period 2012-2015. (2017). FarmaJournal, 2(2), 59-67. https://revistas.usal.es/cinco/index.php/2445-1355/article/view/16013
Similar Articles
- Alfonso Torices, Carmen Guerrero, Terapia antiplaquetaria en cáncer , FarmaJournal: Vol. 6 No. 2 (2021)
- Isabel Rodríguez, Crisanto Martín, Pharmaceutical Care in Probiotics and Immune Stimulation in a Pharmacy Located in Salamanca from September to January 2020 , FarmaJournal: Vol. 6 No. 2 (2021)
- Daniel Salete, Miguel Marcos, Alcohol, Metabolism and Immune System , FarmaJournal: Vol. 8 No. 2 (2023)
- Cira Díez, María José Fernández-Gómez, Javier Martín-Vallejo, Effect of Tobacco Use on Inflammatory Bowel Diseases: Meta-analysis , FarmaJournal: Vol. 7 No. 2 (2022)
- Julia Ausin, Javier Tascón, Alfredo G. Casanova, Laura Vicente-Vicente, Ana I. Morales, Marta Prieto, Nephrotoxicity Associated with the Combination of Cisplatin and Immune Checkpoint Inhibitors. Histopathological Study , FarmaJournal: Vol. 9 No. 1 (2024)
- Javier González, Javier Tascón, Alfredo G. Casanova, Laura Vicente-Vicente, Ana I. Morales, Marta Prieto, Prediction of Immune Checkpoint Inhibitors-Associated Renal Damage in Oncology Patients , FarmaJournal: Vol. 9 No. 2 (2024)
- Sara Revuelta, Javier Tascón, Laura Vicente-Vicente, Alfredo G. Casanova, Ana I. Morales, Marta Prieto, Histological Evaluation of the Nephrotoxicity of Immune Checkpoint Inhibitors , FarmaJournal: Vol. 7 No. 2 (2022)
- Alicia Abril, Javier Tascón, Laura Vicente-Vicente, Alfredo G. Casanova, Marta Prieto, Ana I. Morales, Characterization of Renal Damage Associated with Oncologic Immunotherapy , FarmaJournal: Vol. 8 No. 1 (2023)
- José Alcamí, Vaccines Against Human Immune Deficiency Virus / AIDS , FarmaJournal: Vol. 1 No. 2 (2016)
You may also start an advanced similarity search for this article.
+
−